PMID- 33680572
OWN - NLM
STAT- MEDLINE
DCOM- 20210728
LR  - 20210728
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Print)
IS  - 2162-4011 (Linking)
VI  - 10
IP  - 1
DP  - 2021 Feb 23
TI  - Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in 
      cancer: a systematic review and meta-analysis.
PG  - 1878599
LID - 10.1080/2162402X.2021.1878599 [doi]
LID - 1878599
AB  - Immune checkpoint inhibitors (ICIs) as monotherapy in different solid tumors 
      showed an early detrimental effect in a subset of patients reflected by the early 
      crossover of the progression-free survival (PFS) curves. Currently, combination 
      therapies with ICIs added to chemotherapy or targeted therapy are expanding the 
      landscape of metastatic solid tumors. We have examined the benefits and risks of 
      adding ICIs to the standard of care (SOC) versus SOC alone. A search of 
      randomized clinical trials (RCTs) comparing ICIs combinations versus the 
      corresponding SOC in different metastatic tumors according to the PRISMA 
      guidelines was performed. Selected endpoints included PFS, time-to-response 
      (TTR), overall survival (OS), overall response rate (ORR), and >/= grade 3 adverse 
      events (AEs). Subgroup analyses based on backbone treatment and tumor type were 
      included. A total of 10536 patients (19 studies) were included (ICIs-arm: 5596 
      patients; SOC-arm: 4940 patients). Globally, PFS, OS, and ORR results favored 
      ICIs-arm. No differences in terms of TTR were found between arms. ICI-arm was 
      associated with a slight increase of >/= G3 AEs (relative risk: 1.07). The results 
      in multiple myeloma patients are controversial in favor of ICIs combinations. 
      Adding ICIs to SOC benefits a greater number of patients, prolonging survival 
      with no early detrimental effect. The toxicity profile is safe, with a mild 
      increase of high-grade manageable AEs.
CI  - (c) 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.
FAU - Carretero-Gonzalez, Alberto
AU  - Carretero-Gonzalez A
AD  - Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.
FAU - Otero, Irene
AU  - Otero I
AD  - Medical Oncology Department, Virgen de la Salud Hospital, Toledo, Spain.
FAU - Lora, David
AU  - Lora D
AD  - Clinical Research Unit, IMAS12-CIBERESP, University Hospital 12 de Octubre, 
      Madrid, Spain.
FAU - Carril-Ajuria, Lucia
AU  - Carril-Ajuria L
AD  - Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.
FAU - Castellano, Daniel
AU  - Castellano D
AD  - Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.
FAU - de Velasco, Guillermo
AU  - de Velasco G
AD  - Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20210223
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - *B7-H1 Antigen/therapeutic use
MH  - Humans
MH  - Immune Checkpoint Inhibitors
MH  - *Neoplasms/drug therapy
MH  - Progression-Free Survival
MH  - Standard of Care
PMC - PMC7906255
OTO - NOTNLM
OT  - Immune checkpoint inhibitors
OT  - chemotherapy
OT  - efficacy
OT  - safety
OT  - targeted therapy
EDAT- 2021/03/09 06:00
MHDA- 2021/07/29 06:00
PMCR- 2021/02/23
CRDT- 2021/03/08 05:53
PHST- 2021/03/08 05:53 [entrez]
PHST- 2021/03/09 06:00 [pubmed]
PHST- 2021/07/29 06:00 [medline]
PHST- 2021/02/23 00:00 [pmc-release]
AID - 1878599 [pii]
AID - 10.1080/2162402X.2021.1878599 [doi]
PST - epublish
SO  - Oncoimmunology. 2021 Feb 23;10(1):1878599. doi: 10.1080/2162402X.2021.1878599.